The Auxiliary Effects of Fucoidan for Locally Advanced Rectal Cancer Patients

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Investigate the Auxiliary Effects of Fucoidan in Patients With Locally Advanced Rectal Cancer Who Receive Combined Radio-chemotherapy Before Surgery

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04342949

Enrollment

100

Registered

2020-04-13

Start date

2018-11-09

Completion date

2021-12-31

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRT

Brief summary

This is a double-blind, randomized, placebo-controlled, parallel study. The main goal is to investigate the auxiliary effects of Fucoidan for the patients with locally advanced rectal cancer who receive neoadjuvant CCRT before surgery. The quality of life is our primary endpoint for this study. The study is an observational study.

Interventions

BEHAVIORALquality of life

To observe the difference of quality of life

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Age was more/equal to 20 year-old and less/equal to 80 year-old 2. Diagnosed as locally advanced rectal cancers by pathological biopsy and image study. 3. ECOG performance status within 0 to 2 points 4. Excepted life remaining at least 4 months 5. Females with fertility are willing to use effective contraception during the period of study 6. Willing to follow the test procedures and tracking procedures 7. sign the inform consent form

Exclusion criteria

1.Suffering from other primary malignant tumors 2.Females who are pregnant, planning to become pregnant, or breastfeeding 3.Participate in other interventional clinical trial within the first 30 days 4.Suffering from major mental illness such as mental retardation and mental disorders 5.Unable to understand and answer research questions (oral or written) 6.Abnormal laboratory data within 14 days before joining the study 7.Evidence that subject has a severe or uncontrolled disease \-

Design outcomes

Primary

Measure	Time frame	Description
auxiliary effects of Fucoidan	2 years	To evaluate the quality of life after unblind by 4th edit of FACT-C

Countries

Taiwan

Contacts

Primary ContactHsiang-Lin Tsai, Ph.D

chunpin870132@yahoo.com.tw+88673121101

Backup ContactJaw-Yuan Wang, Ph.D

cy614112@ms14.hinet.net+88673121101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026